IMMUTEP LIMITED - AMERICAN DEPOSITARY SHARES

Immutep Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned

26 10 2022 05:00:01 提供 Nasdaq GlobeNewswire

Immutep Quarterly Activities Report

25 10 2022 05:00:01 提供 Nasdaq GlobeNewswire

Immutep Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

05 10 2022 05:00:02 提供 Nasdaq GlobeNewswire

Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer

04 10 2022 05:00:01 提供 Nasdaq GlobeNewswire

Immutep to Participate in Two Upcoming Investor Conferences

26 9 2022 05:00:02 提供 Nasdaq GlobeNewswire

Immutep Receives A$2.7 million R&D Tax Incentive from French Government

23 9 2022 05:00:00 提供 Nasdaq GlobeNewswire

Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

14 9 2022 05:00:01 提供 Nasdaq GlobeNewswire

Immutep Appoints LAG-3 Pioneer, Frédéric Triebel to Board

13 9 2022 05:00:01 提供 Nasdaq GlobeNewswire

Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

06 9 2022 05:00:03 提供 Nasdaq GlobeNewswire

Immutep Granted Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor

30 8 2022 05:00:01 提供 Nasdaq GlobeNewswire

Immutep Quarterly Activities Report

28 7 2022 05:00:02 提供 Nasdaq GlobeNewswire

Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3

06 7 2022 05:00:02 提供 Nasdaq GlobeNewswire

Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer

27 6 2022 05:00:01 提供 Nasdaq GlobeNewswire

Immutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers

03 6 2022 11:18:08 提供 Nasdaq GlobeNewswire

Immutep Global Webcast to Discuss TACTI-002 Data Presented at ASCO 2022

02 6 2022 05:00:03 提供 Nasdaq GlobeNewswire

Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022

27 5 2022 05:00:00 提供 Nasdaq GlobeNewswire

Immutep to Present at Investor Conferences

20 5 2022 05:00:00 提供 Nasdaq GlobeNewswire

Immutep Appoints Leading Oncologists to its Clinical Advisory Board

18 5 2022 05:00:01 提供 Nasdaq GlobeNewswire

Immutep Presents New and Significant Data from the AIPAC Study

04 5 2022 05:00:02 提供 Nasdaq GlobeNewswire

Immutep Quarterly Activities Report

29 4 2022 05:00:00 提供 Nasdaq GlobeNewswire